Article

Navigating the commercialization of cell and gene therapies

This article was originally published on European Pharmaceutical Review (EPR) on May 19, 2025

Kevin Chinn, VP and Head of Cell and Gene Service Line at Cencora, talks about the hurdles to making cell and gene therapy a commercial success – and how to leap over them.

Read the article to explore the potential and major obstacles impacting cell and gene therapies in the pharmaceutical industry.

Pardot Form

Connect with our cell and gene experts

Schedule some time with our cell and gene experts today. We look forward to hearing from you.
Abstract

Related resources

Article

From AI to regulatory layering and convergence: Key takeaways from RAPS Euro Convergence 2026
Learn more

Article

How U.S. pricing reform is reshaping global market dynamics
Learn more

Guide

Cell and gene therapy playbook for payer engagement: Translating payer expectations into actionable market access strategies
Learn more